The impact of tocilizumab treatment for cytokine release syndrome on the incidence of early blood stream infections after peripheral blood haploidentical hematopoietic cell transplantation

Elisa De Togni, Fei Wan, Michael Slade, Kelly Plach, Ramzi Abboud

Research output: Contribution to journalArticlepeer-review

Abstract

Cytokine release syndrome (CRS) is a potentially fatal systemic inflammatory response that can occur in patients undergoing peripheral blood haploidentical hematopoietic cell transplantation (haplo-HCT). Severe CRS has previously been associated with increased infection risk. IL-6 inhibitors, such as tocilizumab, are useful in moderate to severe CRS, but their effect on infection risk has not been established in this setting. We examined the effect of tocilizumab on blood stream infections (BSIs) in the early post-transplant period in 235 patients who underwent haplo-HCT from 2013 to 2020. Mild CRS was associated with a lower incidence of BSI than severe CRS (OR 0.31, 95% CI 0.13–0.74). In the tocilizumab group, 31% of patients had positive blood cultures versus 14% in the non-tocilizumab group (OR 1.61, 95% CI 0.30–8.60, p = 0.58). However, when controlling for CRS grade, tocilizumab was not independently associated with increased rates of BSIs, suggesting it does not further increase infection risk.

Original languageEnglish
JournalLeukemia and Lymphoma
DOIs
StateAccepted/In press - 2022

Keywords

  • bloodstream infection
  • cytokine release syndrome (CRS)
  • haploidentical
  • hematopoietic stem cell transplantation
  • Tocilizumab

Fingerprint

Dive into the research topics of 'The impact of tocilizumab treatment for cytokine release syndrome on the incidence of early blood stream infections after peripheral blood haploidentical hematopoietic cell transplantation'. Together they form a unique fingerprint.

Cite this